A new publication addressing lixisenatide as part of fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) was published on September 4, 2026. The paper, titled "Use of fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Asians with type 2 diabetes," appears in the journal Primary Care Diabetes.
The publication is indexed under PubMed ID 42697752. As stated in the available event data, this entry marks the release of the article rather than a summary of any specific findings. No results, outcomes, or efficacy data from the paper are included in this brief, as none were provided in the source event information.
Lixisenatide remains an approved compound, and its regulatory status is unaffected by this publication event. Readers interested in the full content of the study, including any methodology or conclusions, are encouraged to consult the journal directly or the linked source.
For more background on lixisenatide, including its general profile and regulatory history, readers can consult the compound overview.